C12N5/079

METHODS FOR PRODUCING NEURAL CELLS
20220403331 · 2022-12-22 ·

The present invention provides differentiated neural cells and methods for making differentiated neural cells from pluripotent stem cells (PSC) at an industrial scale sufficient for high-throughput assays. The methods of the invention allow billions of PSCs and/or neural cells differentiated from the PSCs to be cryopreserved and expanded at multiple steps.

PERFUSION SYSTEM FOR CORNEAL ENDOTHELIAL CELL GRAFT EVALUATION
20220400665 · 2022-12-22 ·

Compositions, devices, and systems comprising a corneal tissue carrier, wherein the corneal tissue carrier comprises a corneal tissue sample and a fluid; wherein the fluid comprises resazurin. Additionally, methods including measuring cell viability.

Composition comprising porous silica particles carrying a cell fate modulating factor

A composition includes porous silica particles to carry a cell fate modulating factor therein. A method for modulating cell fate includes treating various cells with the composition. The cell fate modulating factor is delivered to a stable target receptor, toxicity to subject cells for delivery may be reduced, a fate of the subject cells can be controlled through sustained release of at least 99 wt. % of the cell fate modulating factor.

METHOD FOR EXTRACTING NERVE TISSUE-DERIVED EXOSOMES

Ag-Fe3O4 immunomagnetic microsphere contains poly-D-lysine modified on the surface and S100β and/or MBP antibody linked by an amide bond. The Ag-Fe3O4 immunomagnetic microsphere can specifically capturing peripheral nerve tissue-derived exosomes. When the microsphere is used to extract nerve tissue-derived exosomes, the extraction yield of exosomes per unit volume of nerve tissue is high, and the nerve specificity is strong.

SynP198, a promoter for the specific expression of genes in direction selective retinal ganglion cells

The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 400 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in direction selective retinal ganglion cells of a gene when operatively linked to a nucleic acid sequence coding for said gene.

CORNEAL TISSUE
20220387168 · 2022-12-08 ·

The invention provides an isolated dehydrated corneal tissue, comprising a full thickness corneal stroma, and substantially all, or all, of the Bowman's membrane, wherein the stroma contains cellular material. Also provided is a method to product the tissue and uses of the tissue.

Cultivated Autologous Limbal Epithelial Cell (CALEC) Transplantation
20220387668 · 2022-12-08 ·

Provided herein are methods for generating cultivated autologous limbal epithelial cell grafts for the treatment of various disorders caused by limbal stem cell deficiency. This invention relates to methods and compositions for treating ophthalmic disorders, diseases and injuries. In particular, the field of the invention is directed to methods, kits and compositions for treating disorders, diseases, defects and injuries of the cornea and ocular surface. The present disclosure relates to preparations of cultured mammalian limbal stem cells, derived from corneal limbus tissue.

BRAIN ORGANOID AND USE THEREOF

According to a production method for a brain organoid, comprising a step 1 of carrying out suspension culture of human pluripotent stem cells having a mutation in at least one or more base sequences in an exon selected from the group consisting of an exon 9, an exon 10, an exon 11, an exon 12, and an exon 13 of a microtubule-associated protein tau (MAPT) gene, and having a mutation in at least one or more base sequences in an intron 10 of the MAPT gene, it is possible to produce a brain organoid having a phosphorylated 3-repeat tau protein and a phosphorylated 4-repeat tau protein.

METHOD FOR THE PRODUCTION OF MÜLLER CELLS AND CELL PRODUCT

The present invention relates to a novel process of producing therapeutic GMP grade Müller cells and Miller cells obtainable therefrom, derived from stem cells using products that are free of animal-derived components. The Müller cells are suitable for treatment of eye disease, including glaucoma. There is also provided a cell culture medium.

Artificial Descemet construct

A structured artificial construct that allows corneal endothelium to be regenerated from isolated cells outside the human or animal body is provided. The structured artificial construct is formed from a dome-shaped base body with a honeycomb structure formed in a concave side of the base body. Methods for generating the structured artificial construct are also provided.